Intranasal Budesonide Treatment for Children With Mild Obstructive Sleep Apnea Syndrome
The DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
OBJECTIVES. Intranasal corticosteroids have been advanced as a nonsurgical therapeutic alternative for pediatric obstructive sleep apnea syndrome, particularly for patients with mild disease, and aims at reducing the size of hypertrophic adenotonsillar tissue. METHODS. Of 71 possible candidates, 62 children with polysomnographically diagnosed mild obstructive sleep apnea syndrome were recruited onto a double-blind, randomized, crossover trial of intranasal budesonide (32 μg per nostril at bedtime) or placebo for 6 weeks followed by an additional 6-week treatment in the alternative treatment arm after allowing for a 2-week washout period. Polysomnographic assessment and radiographs for assessment of adenoid size were performed after completion of each phase. RESULTS. There were significant improvements in both polysomnographic measures (sleep latency, slow-wave sleep, and rapid-eye-movement sleep), in the magnitude of respiratory disturbance (apnea/hypopnea index, nadir pulse oxygen saturation), and in adenoid size among the 48 children who completed the treatment phase compared with 32 children who received placebo in their initial arm, with normalization of sleep measures in 54.1% of the treated children. Furthermore, discontinuation of treatment for 8 weeks for 25 children revealed a sustained duration of the initial treatment effect. CONCLUSIONS. A 6-week treatment with intranasal budesonide effectively reduced the severity of mild obstructive sleep apnea syndrome and the magnitude of the underlying adenoidal hypertrophy, and this effect persisted for at least 8 weeks after cessation of therapy. These findings justify the use of topical steroids as the initial therapeutic option in otherwise healthy children with mild obstructive sleep apnea.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As an alternative to T&A for treatment of pediatric OSA, medical treatment has been proposed including nasal steroids and oral montelukast.2123–2125”
From International Consensus Statement on Obstructive Sleep Apnea (2023) · cites this paper as [2124]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 45 · Cited by 272
Metadata
- Authors
- Kheirandish-Gozal, L., & Gozal, D.
- Affiliations
- Division of Pediatric Sleep Medicine, Department of Pediatrics, University of Louisville, Louisville, Kentucky
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2008-07-01
- Volume
- 122
- Issue
- 1
- Pages
- e149-e155
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W1983580599
- Semantic Scholar
- 7ab6d3c6ddbee08135a82a16cb01e3c79da46fc6
- Cited by
- 272
- References
- 45
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 13 · 2023: 11 · 2022: 10 · 2021: 14 · 2020: 13 · 2019: 22 · 2018: 16 · 2017: 17 · 2016: 18 · 2015: 18 · 2014: 23 · 2013: 17 · 2012: 20
- FWCI
- 9.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- PEDIATRICS (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p50hl060296-10)
- National Heart, Lung, and Blood Institute (2P50-HL-60296-06, R01HL069932, HL-65 270, HL-69932, R01HL065270)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Obstructive Sleep Apnea Research
- Health Sciences › Medicine › Otorhinolaryngology › Sinusitis and nasal conditions
- Health Sciences › Medicine › Surgery › Nasal Surgery and Airway Studies
- Keywords
- obstructive sleep apnea, pediatric sleep apnea, intranasal corticosteroids, adenotonsillar hypertrophy, adenoid size, apnea-hypopnea index, sleep-disordered breathing, treatment discontinuation, sustained treatment effects
- MeSH terms
- Adenoids, Administration, Intranasal, Child, Child, Preschool, Double-Blind Method, Female, Glucocorticoids, Humans, Hypertrophy, Infant, Male, Treatment Outcome, Polysomnography, Cross-Over Studies, Budesonide, Sleep Apnea, Obstructive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intranasal Budesonide Treatment for Children With Mild Obstructive Sleep Apnea Syndrome. https://app.cochat.ai/papers/10.1542/peds.2007-3398
- The paper
- Kheirandish-Gozal, L., & Gozal, D. (2008). Intranasal Budesonide Treatment for Children With Mild Obstructive Sleep Apnea Syndrome. Pediatrics. https://doi.org/10.1542/peds.2007-3398
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.